{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:21:48Z","timestamp":1790248908402,"version":"4.1.0"},"reference-count":37,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/501100001862","name":"The Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009332","name":"Mag-TarmFonden, Swedish Gastroenterology Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Type 2 diabetes (T2D) increases the risk for major adverse liver outcomes (MALOs), including cirrhosis and its complications. Patients with T2D frequently have other traits of the metabolic syndrome (MetS). It remains uncertain whether there is a synergistic effect of accumulating MetS traits on future MALO risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Patients with T2D without a history of liver disease were identified from national registers in Sweden from 1998 to 2021. MetS traits included hypertension, low HDL level, hypertriglyceridemia, obesity, and albuminuria, in addition to T2D. MALO events were identified based on administrative coding from national registers until 31 October 2022. Data were analyzed using Cox regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>In total, 230,992 patients were identified (median age 64 years; 58% male), of whom 3,215 (1.39%) developed MALOs over a median follow-up of 9.9 years. Compared with patients with one MetS trait (only T2D) at baseline, those with more than one MetS trait had a higher rate of MALOs (adjusted hazard ratio [aHR] 2.33, 95% CI 1.53\u20133.54). The rate of MALOs increased progressively with increasing numbers of MetS traits at baseline (aHR 1.28 per added trait, 95% CI 1.23\u20131.33). During follow-up, patients who acquired additional MetS traits had a progressively higher rate of MALOs. The MetS trait with the largest association with incident MALOs was hypertension (aHR 2.06, 95% CI 1.57\u20132.71).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Having or acquiring additional traits of MetS increase the rate of progression to MALOs in patients with T2D. These results could be used to inform screening initiatives for liver disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc23-1937","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T12:29:17Z","timestamp":1710764957000},"page":"978-985","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":58,"title":["Metabolic Syndrome Traits Increase the Risk of Major Adverse Liver Outcomes in Type 2 Diabetes"],"prefix":"10.2337","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-1799","authenticated-orcid":false,"given":"Ying","family":"Shang","sequence":"first","affiliation":[{"name":"1Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie Toresson","family":"Grip","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden"},{"name":"2Quantify Research, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Modica","sequence":"additional","affiliation":[{"name":"3Pfizer AB, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Skr\u00f6der","sequence":"additional","affiliation":[{"name":"2Quantify Research, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Str\u00f6m","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden"},{"name":"2Quantify Research, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Ntanios","sequence":"additional","affiliation":[{"name":"4U.S. Medical Affairs, Pfizer Inc., New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soffia","family":"Gudbj\u00f6rnsdottir","sequence":"additional","affiliation":[{"name":"5Swedish National Diabetes Register"},{"name":"6Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden"},{"name":"7Division of Hepatology, Department of Upper GI Diseases, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"2024052018524958500_B1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024052018524958500_B2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"2024052018524958500_B3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"2024052018524958500_B4","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/j.cgh.2019.04.038","article-title":"Risk factors for severe liver disease in patients with type 2 diabetes","volume":"17","author":"Bj\u00f6rkstr\u00f6m","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024052018524958500_B5","doi-asserted-by":"crossref","first-page":"100411","DOI":"10.1016\/j.jhepr.2021.100411","article-title":"Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions","volume":"4","author":"Anstee","year":"2021","journal-title":"JHEP Rep"},{"key":"2024052018524958500_B6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"2024052018524958500_B7","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"key":"2024052018524958500_B8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S2468-1253(22)00020-6","article-title":"Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review","volume":"7","author":"Abeysekera","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024052018524958500_B9","first-page":"293","volume":"77","author":"Rowe","year":"2022"},{"key":"2024052018524958500_B10","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0168-8227(14)70732-6","article-title":"Diabetes care--improvement through measurement","volume":"106","author":"Eliasson","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2024052018524958500_B11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"2024052018524958500_B12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2024052018524958500_B13","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/00365521.2020.1820566","article-title":"Validity of administrative codes associated with cirrhosis in Sweden","volume":"55","author":"Bengtsson","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"2024052018524958500_B14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"2024052018524958500_B15","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1464-5491.2005.01648.x","article-title":"The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996\u20132003","volume":"22","author":"Eliasson","year":"2005","journal-title":"Diabet Med"},{"key":"2024052018524958500_B16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CLEP.S282475","article-title":"Adaptation of the Charlson comorbidity index for register-based research in Sweden","volume":"13","author":"Ludvigsson","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2024052018524958500_B17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"key":"2024052018524958500_B18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish Cause of Death Register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"2024052018524958500_B19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2307\/2532940","article-title":"Applying Cox regression to competing risks","volume":"51","author":"Lunn","year":"1995","journal-title":"Biometrics"},{"key":"2024052018524958500_B20","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/ije\/dyr213","article-title":"Competing risks in epidemiology: possibilities and pitfalls","volume":"41","author":"Andersen","year":"2012","journal-title":"Int J Epidemiol"},{"key":"2024052018524958500_B21","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/ijc.30506","article-title":"Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: a nationwide nested case-control study","volume":"140","author":"Kim","year":"2017","journal-title":"Int J Cancer"},{"key":"2024052018524958500_B22","doi-asserted-by":"crossref","first-page":"e40376","DOI":"10.1371\/journal.pone.0040376","article-title":"The PNPLA3 rs738409 G-allele associates with reduced fasting serum triglyceride and serum cholesterol in Danes with impaired glucose regulation","volume":"7","author":"Krarup","year":"2012","journal-title":"PLoS One"},{"key":"2024052018524958500_B23","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/hep.26767","article-title":"Association between the PNPLA3 (rs738409 C&gt;G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data","volume":"59","author":"Tr\u00e9po","year":"2014","journal-title":"Hepatology"},{"key":"2024052018524958500_B24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease","volume":"78","author":"\u00c5berg","year":"2023","journal-title":"J Hepatol"},{"key":"2024052018524958500_B25","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/liv.14830","article-title":"Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: a population-based study","volume":"41","author":"Pose","year":"2021","journal-title":"Liver Int"},{"key":"2024052018524958500_B26","doi-asserted-by":"crossref","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PLoS Med"},{"key":"2024052018524958500_B27","doi-asserted-by":"crossref","first-page":"8463640","DOI":"10.1155\/2022\/8463640","article-title":"Bidirectional association between hypertension and NAFLD: a systematic review and meta-analysis of observational studies","volume":"2022","author":"Li","year":"2022","journal-title":"Int J Endocrinol"},{"key":"2024052018524958500_B28","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/gast.2002.33650","article-title":"Diabetes increases the risk of acute hepatic failure","volume":"122","author":"El-Serag","year":"2002","journal-title":"Gastroenterology"},{"key":"2024052018524958500_B29","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"59","author":"European Association for the Study of the Liver (EASL)","year":"2016","journal-title":"Diabetologia"},{"key":"2024052018524958500_B30","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.1840120505","article-title":"Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors","volume":"12","author":"Wanless","year":"1990","journal-title":"Hepatology"},{"key":"2024052018524958500_B31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2337\/diacare.22.5.756","article-title":"Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study","volume":"22","author":"de Marco","year":"1999","journal-title":"Diabetes Care"},{"key":"2024052018524958500_B32","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s10620-016-4261-8","article-title":"Diabetes is associated with clinical decompensation events in patients with cirrhosis","volume":"61","author":"Liu","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2024052018524958500_B33","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajg.2014.132","article-title":"Mortality from chronic liver diseases in diabetes","volume":"109","author":"Zoppini","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2024052018524958500_B34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00125-005-0063-9","article-title":"Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes","volume":"49","author":"Guzder","year":"2006","journal-title":"Diabetologia"},{"key":"2024052018524958500_B35","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"2024052018524958500_B36","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.cgh.2017.02.040","article-title":"Waist\/hip ratio better predicts development of severe liver disease within 20 years than body mass index: a population-based cohort study","volume":"15","author":"Andreasson","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024052018524958500_B37","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/6\/978\/764782\/dc231937.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/6\/978\/764782\/dc231937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T14:55:47Z","timestamp":1716216947000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/6\/978\/154337\/Metabolic-Syndrome-Traits-Increase-the-Risk-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3,18]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-1937","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}